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Abstract: Short-term duodenal administration of n-3 polyunsaturated fatty acid (PUFA)-rich 
seal oil may improve gastrointestinal complaints in patients with subjective food hypersensitivity, 
as well as joint pain in patients with inﬂammatory bowel disease (IBD). The aim of the present 
explorative pilot study was to investigate whether 10-day open treatment with seal oil, 10 mL 
self-administrated via a nasoduodenal tube 3 times daily, could also beneﬁt nongastrointestinal 
complaints and quality of life (QoL) in patients with subjective food hypersensitivity. Twenty-six 
patients with subjective food hypersensitivity, of whom 25 had irritable bowel syndrome (IBS), 
were included in the present study. Before and after treatment and 1 month posttreatment, patients 
ﬁlled in the Ulcer Esophagitis Subjective Symptoms Scale (UESS) and the Gastrointestinal 
Symptom Rating Scale (GSRS) for gastrointestinal symptoms and subjective health complaints 
(SHC) inventory for nongastrointestinal symptoms in addition to short form of the Nepean dys-
pepsia index (SF-NDI) for evaluation of QoL. Compared with baseline, gastrointestinal, as well 
as nongastrointestinal, complaints and QoL improved signiﬁcantly, both at end of treatment and 
1 month posttreatment. The consistent improvements following seal oil administration warrant 
further placebo-controlled trials for conﬁrmation of effect.
Keywords: food hypersensitivity, irritable bowel syndrome, subjective health complaints, 
quality of life, seal oil, n-3 polyunsaturated fatty acids
Introduction
Although about 20% of the general population report having adverse reactions to 
food, food allergy is medically conﬁrmed in only 1%–2% of adults.1,2 Patients with 
subjective food hypersensitivity present with unexplained gastrointestinal complaints, 
which they self-attribute to the ingestion of speciﬁc foods. Usually, the gastrointestinal 
complaints comply with the Rome-II criteria for irritable bowel syndrome (IBS).3,4 
Nongastrointestinal complaints are prevalent, and health-related quality of life (QoL) 
is often considerably impaired.3,5
Subjective health complaints (SHC) are major health problems as they are the 
most frequent sources for long-term sickness and permanent inability to work.6 The 
pathogenesis of subjective food hypersensitivity, as of SHC in general, is not well 
understood. Central sensitization, in which cognitive as well as somatic sensitization 
contribute to ampliﬁcation of the complaints, is a widely accepted explanatory model.7 
Compared to the general population, patients with subjective food hypersensitivity 
report more frequent and severe SHC.5 As usual, in case of multiple unexplained 
complaints from various organ systems, psychological mechanisms are suspected. 
Thus, cognitive sensitization has been suggested as a much more important cause 
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of subjective food hypersensitivity than immunological 
sensitization.5 This assumption is supported by ﬁndings of 
increased prevalence of anxiety and depression in patients 
with IBS and subjective food hypersensitivity8 and the fact 
that anxiety and depression often present with somatic rather 
than emotional symptoms.9,10 However, psychological factors 
are not major predictors of symptom severity in patients with 
subjective food hypersensitivity.11
By using a SHC inventory, Lind et al found musculoskeletal 
pain and fatigue to be common among patients with subjec-
tive food hypersensitivity.5 Indeed, subjective food hyper-
sensitivity with IBS-like symptoms, joint pain, and fatigue 
appear to be increasingly recognized worldwide.12 Long-term 
per oral administration of long-chain n-3 polyunsaturated 
fatty acids (PUFAs)-rich ﬁsh oil is known to relieve joint pain 
in patients with rheumatoid arthritis,13 an effect supposed to 
be in part due to inhibition of eicosanoid synthesis. The most 
abundant PUFA in human cell membrane phospholipids, the 
n-6 fatty acid arachidonic acid (AA, 2:4n-6), is liberated upon 
stimulation and generally gives rise to more proinﬂamma-
tory eicosanoids via the cyclooxygenase and lipooxygenase 
pathways. The long-chain n-3 PUFAs, especially eicosapen-
taenoic acid (EPA; 20:5n-3), cause a shift in cyclooxygenase 
and lipooxygenase pathways, producing less proinﬂamma-
tory mediators.14 Intriguingly, Clarke et al recently found 
elevated plasma AA and prostaglandin E
2
 (PGE
2
) levels in 
patients with IBS compared to healthy controls.15 Seal oil 
is slightly less rich in the n-3 long-chain PUFAs EPA and 
docosahexaenoic acid (DHA; 22:6n-3), but contains more of 
docosapentaenoic acid (DPA; 22:5n-3), compared to ﬁsh oil.16 
In recent studies, short-term duodenal administration of seal 
oil,17,18 but not n-6 fatty acid-rich soy oil,19,20 attenuated joint 
pain with prolonged effects in patients with inﬂammatory 
bowel disease (IBD).19 Compared with soy oil, short-term 
seal oil administration via nasoduodenal tube also relieved 
gastrointestinal symptoms in patients with subjective food 
hypersensitivity.20
The aim of the present explorative pilot study was to 
investigate whether 10-day open duodenal administration of 
seal oil could attenuate also nongastrointestinal symptoms 
and improve QoL in patients with subjective food hypersen-
sitivity. In case of positive effects, further placebo-controlled 
trials would be warranted.
Material and methods
Screening of patients
Consecutive outpatients referred to Haukeland University 
Hospital due to various unexplained gastrointestinal 
complaints self-attributed to specific food items were 
eligible for inclusion in the study. The patients were care-
fully examined to exclude organic diseases such as peptic 
ulcer, Helicobacter pylori infection, celiac disease, IBD, 
and parasitic infections as previously described.21 Pregnant 
or lactating women were also excluded. The allergological 
examination included skin prick tests using 22 common food 
items and inhalants (ALK, Abello, Hørsholm, Denmark), 
blood samples for determination of both serum total IgE 
and food-speciﬁc IgE levels (ImmunoCap-System, Phadia, 
Uppsala, Sweden), and, when indicated, open and double-
blind provocation tests. Twenty-six of 68 (38%) screened 
patients were willing to participate in the present study. The 
majority of the patients were women (F/M, 23/3), and the 
mean age was 47 years, with range 26–88 years.
Study design
Reﬁned seal oil (Rieber Skinn A/S, Bergen, Norway) from 
adult harp seals (Pagophilus groenlandicus) was adminis-
tered by a nasoduodenal feeding tube, which was inserted 
at start of the 10-day intervention period. The tube (Freka® 
Feeding Tube, Fresenius Kabi, GmbH, Hesse, Germany) 
was positioned with its tip to the lower duodenum by aid 
of ﬂuoroscopy. As in our prior studies,17–20 the patients 
self-administered 10 mL of seal oil via the tube, 3 times/
day for 10 days, while they were instructed not to alter their 
background diet. This amount of seal oil is equivalent to a 
daily intake of approximately 2.4 g EPA, 1.1 g DPA, and 
2.6 g DHA, that is, 6.1 g of long-chain n-3 PUFA, which is 
approximately the double dose of that required to achieve 
anti-inﬂammatory effect in rheumatoid arthritis (2.7 g EPA 
and DHA day1).13
Before and after seal oil treatment and at day 30 posttreat-
ment, the patients ﬁlled in previously validated Norwegian ver-
sions of questionnaires for SHC, the short form of the Nepean 
dyspepsia index (SF-NDI) for assessment of QoL, and two 
questionnaires regarding gastrointestinal complaints, namely, 
the Gastrointestinal Symptom Rating Scale (GSRS) and the 
Ulcer Esophagitis Subjective Symptoms Scale (UESS).
The Regional Ethical Research Committee approved the 
study, which was performed in accordance with the Helsinki 
Declaration, and all participants gave written informed con-
sent before inclusion in the study.
Experimental oil
The reﬁned seal oil used in the present study was approved 
according to current legislations on contaminants. The 
fatty acid composition in the oil was analyzed by gas  liquid 
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chromatography (Trace GC 2000) according to previ-
ously described methods,17,22 with some modiﬁcations; the 
fatty acids were esteriﬁed in 20% boron ﬂuoride (BF
3
) in 
methanol, and sample parallels were analyzed. The level 
of fat soluble vitamins A23,24 and E25 was analyzed by 
high-performance liquid chromatography, and the lipid 
peroxidation was analyzed by thiobarbituric acid reactive 
substances26,27 (Table 1). The seal oil was added with a 
combination of natural and synthetic tocopherols, the latter 
being dl-A tocopheryl acetate. The oil was protected with 
nitrogen on top in bottles and stored in a refrigerator during 
study, otherwise in 20oC freezer.
Subjective health complaint inventory
The SHC inventory includes 29 items concerning somatic and 
psychological complaints.28 The questionnaire contains ﬁve 
subscales: musculoskeletal pain (migraine, headache, arm pain, 
shoulder pain, neck pain, upper back pain, lower back pain, and 
leg pain), gastrointestinal complaints (gas discomfort, stomach 
discomfort, gastritis/ulcer, heartburn, diarrhea, constipation, 
and stomach pain), allergy (allergies, breathing difﬁculties, 
eczema, and asthma), pseudoneurology (tiredness, sleep 
problems, dizziness, heat ﬂushes, extra heartbeats, sadness/
depression, and anxiety), and ﬂu (cold/ﬂu and coughing). The 
scores were determined by rating each item by a four-point 
graded Likert scale ranging from 0 (not at all), 1 (a little), 2 
(quite a lot) to 3 (severely). The questionnaire has been tested 
with satisfactory validity and reliability outcome.28
Gastrointestinal symptom rating scale
The questionnaire includes 15 items, which are grouped into 
ﬁve subscales: abdominal pain syndrome (abdominal pain/
discomfort, sucking sensation in the epigastrium, nausea, 
and vomiting), reflux syndrome (heartburn and acidic 
regurgitation), indigestion (borborygmi, abdominal disten-
sion, eructation, and increased ﬂatus), diarrhea (increased 
passage of stools, loose stools, and urgent need for defeca-
tion), and constipation (decreased passage of stools, hard 
stools, and feeling of incomplete evacuation). The scores 
were determined by rating each item by a seven-point graded 
Likert scale with descriptive anchors (1, no symptoms at 
all; 2, minimal symptoms; 3, mild symptoms; 4, moderate 
symptoms; 5, rather serious symptoms; 6, serious symptoms; 
and 7, very serious symptoms). A Norwegian version of the 
GSRS was used in the present study.29
Ulcer Esophagitis Subjective  
Symptoms Scale
The UESS was developed to examine the symptoms frequently 
experienced by patients with peptic ulcer and esophagitis. The 
questionnaire includes nine items, which are grouped into four 
subscales: abdominal discomfort (abdominal pain and sucking 
sensation), reﬂux discomfort (acid regurgitation and heartburn), 
intestinal discomfort (abdominal distension and borborygmi), 
and sleep dysfunction (difﬁculty falling asleep, insomnia, and 
rested waking up).30 A Norwegian version of the UESS was 
used in the present study.29 The scores were determined by 
rating each item by a 100-mm horizontal visual analog scale 
ranging from 0 (very well) to 100 (very poor). This Norwegian 
version of visual analog scale has previously been validated 
in terms of reliability, validity, and sensitivity.31
Short form of the Nepean  
dyspepsia index
The SF-NDI is a 10-item questionnaire with ﬁve subscales 
measuring the inﬂuence of dyspepsia on domains of health-
related QoL, namely, tension, interference with daily activities, 
Table 1 Fatty acid profile (g/100 g), vitamins A and E and thiobarbituric 
acid reactive substances in seal oil
Analyte Seal oil
14:0 4.5
16:0 8.0
18:0 1.2
3 saturated 14.2
16:1n-7 14
18:1n-11 3.2
18:1n-9 14.9
18:1n-7 3.8
20:1n-11 1.6
20:1n-9 7.7
22:1n-11 1.8
3 monoenes 48.9
18:2n-6 1.5
20:4n-6 0.6
3n-6 2.2
18:3n-3 0.6
18:4n-3 1.6
20:4n-3 0.5
20:5n-3 7.9
22:5n-3 3.7
22:6n-3 8.6
3n-3 23.9
n-6/n-3 0.1
3 vitamin A 0.3 mg/100 g
A-Tocopherol 4.5 mg/100 g
TBARS 3.6 nmol/g w/w
Note: Values are means of two analytical replicates.
Abbreviations: Monoenes, monounsaturated fatty acids; Sum vitamin A, 
sum retinol (13-, 11-, 9-cis and all-trans retinol, ie, A1), and 3,4 didehydro-
all-trans retinol A2); TBARS, thiobarbituric acid reactive substances; w/w, 
wet weight.
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altered eating/drinking habits, knowledge/control over disease 
symptoms, and interference with work/study, and each subscale 
contains two items.32 The scores were determined by measuring 
each item by a ﬁve-point graded Likert scale ranging from 1 
(not at all or not applicable), 2 (a little), 3 (moderately), 4 (quite 
a lot) to 5 (extremely). The total sum score for QoL ranges 
from 10 to 50, and the sum score of each of the ﬁve subscales 
ranges from 2 to 10. Higher scores indicate poorer QoL. The 
10-item SF-NDI has been validated in patients with functional 
dyspepsia,32 as well as in patients with subjective food hyper-
sensitivity.3 The questionnaire gives consistent outcome, and 
the stability of the test–retest results suggest that the chance of 
spontaneous regression of symptoms reported by the SF-NDI 
in patients with subjective food hypersensitivity is small.
Statistics
Data were analyzed and displayed using the GraphPad 
Prism statistical software package (GraphPad Prism version 
5.00 for Windows, GraphPad Software, San Diego, CA, 
USA). Results are presented as individual values and as 
mean p standard error of mean (SEM). Differences in total 
sum scores and total subscale scores were evaluated by paired 
student t-tests. All tests were two-tailed, and P values  0.05 
were regarded statistically signiﬁcant.
Resul ts
Patient characteristics at baseline
Most patients reported adverse reactions to three or four 
food items: cow’s milk (54%), diverse fruits (38%), and 
raw vegetables (35%) being most common (Table 2). All 
patients had negative tests for Helicobacter pylori infec-
tion, celiac disease, and parasitic infections. Double-blind 
placebo-controlled food challenge was positive in three 
patients having non-IgE-mediated allergy or nonallergic food 
hypersensitivity. None of the patients had IgE-mediated food 
allergy as conﬁrmed by both skin prick tests, food-speciﬁc 
IgE levels in serum, and double-blind placebo-controlled 
food challenge with the same food item. Twenty-ﬁve of the 
26 patients had IBS according to the Rome II criteria.
Subjective health complaints
Total sum score of the SHC inventory was 24.3 p 2.2 before 
seal oil treatment, 17.4 p 1.9 after 10 days, taking 30 mL 
seal oil/day, and 20.1 p 2.0 one month posttreatment. There 
was a signiﬁcant difference in the total sum score between 
before and after 10-day seal oil treatment (P  0.0001) and 
between before and 30 days after the seal oil treatment was 
ended (P  0.0008) (Figure 1).
Subscale scores for SHC were highest for musculoskeletal 
and gastrointestinal complaints. As compared with pretreatment, 
the musculoskeletal pain score was signiﬁcantly decreased after 
10-day seal oil treatment from 7.1 p 0.9 to 4.6 p 0.7 (P  0.01). 
The gastrointestinal complaint score was significantly 
decreased from 6.9 p 0.6 to 5.0 p 0.6 (P  0.01) 30 days after 
seal oil treatment. Subscale sum score for pseudoneurology was 
also signiﬁcantly decreased, both at 10 days (P  0.01) and at 
30 days posttreatment (P  0.05) (Table 3).
The ﬁve most frequently reported complaints were tired-
ness (92%), diarrhea (92%), gas discomfort (85%), stomach 
pain (81%), and headache (81%) (Table 4). Each patient 
reported at least four complaints. Five to ten complaints 
were reported by six patients (23%), 11–15 complaints by 
seven patients (27%), whereas 12 patients reported more 
than 15 complaints (46%).
Quality of life
Total sum score of the SF-NDI was 28.2 p 1.2 before the seal 
oil treatment, 19.5 p 1.3 after 10-day seal oil treatment, and 
19.9 p 1.3 one month after completion of seal oil treatment. 
The decrease from baseline was signiﬁcant both at 10 days 
(P  0.0001) and at 30 days posttreatment (P  0.0008) 
(Figure 2).
The six subscale scores were all signiﬁcantly reduced 
after 10 days’ treatment. The highest subscale score was 
for eating/drinking (7.1 p 0.4), and the lowest score was for 
knowledge/control (4.7 p 0.3) (Table 5).
Abdominal complaints
Total sum scores for GSRS before the seal oil treatment was 
35.1 p 2.3, after 10-day seal oil treatment was 26.4 p 2.7, 
and 30 days after completion of seal oil treatment was 
Table 2 Food items suspected by patients to cause food hypersensitivity
Food items Number of patients Percentage
Milk 16 62
Fruit1 12 46
Raw vegetables 9 35
Orange juice 9 35
Whole grain bread 7 27
Egg 7 27
Berries2 5 19
Alcohol 5 19
Gluten 5 19
Fried food 5 19
Spices 4 15
Coffee 4 15
Notes: 1Most reported: citrus fruits, apple, kiwi, and pear; 2Most reported: 
strawberry, all types.
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Figure 1 Total sum score for SHC in patients with self-reported food hypersensitivity (n  26), measured before and after seal oil treatment, and 1 month posttreatment. 
Individual values are displayed, and P values are indicated.
Table 3 SHC: Mean score p SEM for total sum and subscales before seal oil, 10 days after seal oil, and 1 month posttreatment with seal oil
Subscales Before 
seal oil
After 10 days 
of seal oil
One month 
posttreatment
Before versus 
10 days
Before versus 
1 month
Total sum 24.3 p 2.2 17.4 p 1.9 20.1 p 2.0 P  0.01 P  0.01
Musculoskeletal pain  7.1 p 0.9  4.6 p 0.7  6.3 p 0.9 P  0.01 n.s
Pseudoneurology  5.6 p 0.6  3.5 p 0.5  3.9 p 0.6 P  0.01 P  0.05
Gastrointestinal 
complaints
 6.9 p 0.6  6.1 p 0.8  5.0 p 0.6 n.s P  0.01
Allergies  3.7 p 0.7  3.4 p 0.8  2.5 p 0.5 n.s P  0.05
Flu  1.5 p 0.3  0.8 p 0.2  1.5 p 0.4 P  0.05 n.s
26.5 p 2.8. The decrease from baseline was signiﬁcant both 
at 10 days (P  0.007) and at 30 days posttreatment (P  0.02) 
(Figure 3).
Total sum score for UESS before the seal oil treat-
ment was 39.1 p 2.7, after 10 days with seal oil treatment 
was 24.0 p 2.4, and 30 days after completion of seal oil 
treatment was 28.3 p 3.3. The decrease from baseline was 
signiﬁcant both at 10 days (P  0.0001) and at 30 days post-
treatment (P  0.0006) (Figure 3).
Compared with baseline, the abdominal pain syndrome 
and the diarrhea subscale scores on the GSRS were signiﬁ-
cantly decreased both at 10 days and at 1 month posttreatment 
(abdominal pain syndrome: P  0.05; diarrhea: P  0.01), and 
the indigestion subscale score was signiﬁcantly decreased at 
10 days (P  0.05) (Table 5). Likewise, the intestinal discom-
fort and sleep dysfunction subscale scores on the UESS were 
signiﬁcantly decreased both at 10 days and at 1 month after 
completion of seal oil treatment (P  0.01), and the abdominal 
discomfort subscale score was signiﬁcantly decreased after 
10 days (P  0.05) (Table 6). The most reported complaints 
on the GSRS were indigestion, diarrhea, and abdominal 
complaints. On the UESS, sleep dysfunction, abdominal 
complaints, and intestinal complaints had the highest scores. 
Reﬂux symptoms had lowest scores on both questionnaires.
Discussion
The present study concerns patients who attribute their 
IBS-like complaints to the ingestion of food. Besides the 
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Table 4 Number (percentage) of individuals with complaints for each item of the SHC inventory before seal oil, 10 days after seal oil, and 1 month 
posttreatment with seal oil
Before seal oil After 10 days 
of seal oil
One month 
posttreatment
Musculoskeletal pain
Headache 21 (81) 16 (62) 18 (69)
Neck pain 19 (73) 10 (38) 16 (62)
Upper back pain 12 (46) 6 (23) 9 (35)
Lower back pain 18 (69) 15 (58) 18 (69)
Arm pain 10 (38) 10 (38) 11 (42)
Shoulder pain 14 (54) 7 (27) 15 (58)
Migraine 6 (23) 4 (15) 9 (35)
Leg pain during physical 
work
13 (50) 9 (35) 12 (46)
Pseudoneurology
Extra heartbeats 8 (31) 6 (23) 8 (31)
Heat flushes 10 (38) 8 (31) 5 (19)
Sleep problems 15 (58) 14 (54) 12 (46)
Tiredness 24 (92) 23 (88) 22 (85)
Anxiety 17 (65) 9 (35) 9 (35)
Sadness/depression 5 (19) 4 (15) 5 (19)
Dizziness 6 (23) 8 (31) 8 (31)
Gastrointestinal problems
Heartburn 12 (46) 10 (38) 10 (38)
Stomach discomfort 12 (46) 11 (42) 12 (46)
Gastritis, ulcer 3 (12) 3 (12) 1 (4)
Stomach pain 21 (81) 20 (77) 17 (65)
Gas discomfort 22 (85) 23 (88) 22 (85)
Diarrhea 24 (92) 14 (54) 18 (69)
Constipation 9 (35) 12 (46) 8 (31)
Allergies
Allergy 10 (38) 8 (31) 6 (23)
Breathing difficulties 13 (50) 8 (31) 10 (38)
Eczema 10 (38) 9 (35) 8 (31)
Asthma 16 (62) 11 (42) 10 (38)
Chest pain 11 (42) 9 (35) 9 (35)
Flu
Cold/flu 12 (46) 12 (46) 11 (42)
Coughing 12 (46) 10 (38) 10 (38)
avoidance of certain food items, a range of therapies, such as 
dietary ﬁbers, antispasmodics, antidepressants, 5-HT
3
 antago-
nists, 5-HT
4
 agonists, probiotics, and cognitive therapies, 
are used in IBS. But in general, the effect of the treatment 
is modest and inconsistent. Although a biopsychosocial 
model is well accepted, considerable disagreement exists as 
to whether the treatment should be focused on the somatic or 
on the psychological aspects of the condition.33 Indeed, we 
recently showed that 90% of the variance in symptoms sever-
ity in patients with subjective food hypersensitivity is not 
explained by psychological factors.11 Thus, further explora-
tion of possible nonpsychological treatments is well justiﬁed. 
Interestingly, following 10-day intraduodenal administration 
of seal oil in the present study, gastrointestinal, as well as 
nongastrointestinal, symptoms were signiﬁcantly attenuated 
and QoL was consistently improved. The results thus cor-
roborate our previous ﬁndings of beneﬁcial effects of simi-
larly administrated seal oil on gastrointestinal complaints in 
patients with subjective food hypersensitivity and on joint 
pain in patients with IBD.19,20
As in a prior study, our patients scored high on both gas-
trointestinal and nongastrointestinal complaints on the SHC 
inventory.3,5 The high scores for gastrointestinal complaints 
were indeed expected, being the main cause for seeking medi-
cal help. The high scores on musculoskeletal complaints, tired-
ness, sleep problems, and anxiety show that nongastrointestinal 
complaints are highly relevant problems for patients with sub-
jective food hypersensitivity. Thus, it may be valuable to assess 
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Figure 2 Total sum score for SF-NDI in patients with self-reported food hypersensitivity (n  26), measured before and after seal oil treatment, and 1 month posttreatment. 
Individual values are displayed, and P values are indicated.
Table 5 QoL on SF-NDI: Mean score p SEM for total sum and subscales before seal oil, 10 days after seal oil, and 1 month posttreatment with seal oil
Subscales Before 
seal oil
After 10 days 
of seal oil
One month 
posttreatment
Before versus 
10 days
Before versus 
1 month
Total sum 28.0 p 1.2 19.5 p 1.3 19.9 p 1.3 P  0.01 P  0.01
Tension  5.9 p 0.3  4.2 p 0.4  4.0 p 0.3 P  0.05 P  0.01
Interference with 
daily activity
 5.4 p 0.4  4.1 p 0.3  3.5 p 0.3 P  0.01 P  0.01
Eating/drinking  7.1 p 0.4  4.5 p 0.3  5.0 p 0.4 P  0.01 P  0.01
Knowledge/control  4.7 p 0.3  3.3 p 0.2  3.1 p 0.2 P  0.01 P  0.01
Work/study  5.1 p 0.4  4.0 p 0.4  3.5 p 0.3 P  0.05 P  0.01
Note: P values are indicated.
SHC and QoL in future treatment studies in these patients. 
Although tube administration is an invasive and cumbersome 
procedure, the treatment was remarkably well tolerated and 
largely without side effects. The therapeutic beneﬁt observed 
following this short-term therapy suggests that a rapid effect is 
achieved by administrating seal oil directly into the duodenum 
using feeding tube.17–20,34 No direct comparative study of oral 
versus duodenal administration of marine oils for pain relief 
exists, but it is worth noticing that seal oil orally administrated 
for 14 days showed no signiﬁcant effect in patients with IBD 
or psoriatic arthritis.35,36 Thus, it is possible that pain relief 
by marine oils is achieved more rapidly by intraduodenal 
administration compared to oral administration, and an effect 
within 10 days may be possible by tube administration only. 
This form of administration was, therefore, chosen in this 
explorative pilot study. The use of nasoduodenal tube also 
ensures compliance regarding intake of the oil.
Indications of immune activation have been shown both 
in patients with IBS37,38 and in patients with subjective food 
hypersensitivity.21,39 The anti-inﬂammatory effect of long-
chain PUFA is supposed to be brought about by modula-
tion of the amount and types of eicosanoids produced via 
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Table 6 Mean score (pSEM) for subscales in GSRS and UESS before seal oil, 10 days after seal oil, and 1 month posttreatment with seal oil
Subscales Before 
seal oil
After 10 days 
of seal oil
One month 
posttreatment
Before versus 
10 days
Before versus 
1 month
GSRS (Likert scale 1–7)
Abdominal pain syndrome  8.2 p 0.6 6.5 p 0.7 6.2 p 0.8 P  0.05 P  0.05
Reflux syndrome  2.2 p 0.4 1.9 p 0.5 1.4 p 0.4 n.s n.s
Indigestion 10.4 p 1.1 7.8 p 0.9 8.0 p 0.9 P  0.05 n.s
Diarrhea  8.6 p 0.7 5.0 p 0.8 5.9 p 0.9 P  0.01 P  0.01
Constipation  4.3 p 0.8 4.0 p 0.8 3.9 p 0.9 n.s n.s
UESS (100 mm VAS)
Abdominal discomfort 12.3 p 1.2 9.4 p 1.3 9.7 p 1.5 P  0.05 n.s
Reflux discomfort  3.2 p 0.7 2.0 p 0.6 2.5 p 0.6 n.s n.s
Intestinal discomfort  9.9 p 1.0 5.9 p 1.0 6.4 p 1.0 P  0.01 P  0.01
Sleep dysfunction 13.5 p 1.2 7.4 p 1.0 7.3 p 1.0 P  0.01 P  0.01
Note: P values are indicated.
Abbreviation: VAS, visual analog scale.
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Figure 3 Total sum score for GSRS A) and UESS B) in patients with self-reported food hypersensitivity (n  26), measured before and after seal oil treatment, and 1 month 
posttreatment. Individual values are displayed and P values are indicated.
the cyclooxygenase and lipooxygenase enzyme pathways. 
Consistently, plasma levels of proinﬂammatory PGE
2
 was 
reduced in response to 10-day treatment with duodenal 
administered seal oil in patients with IBD-related joint pain.18 
Other effects may be eicosanoid-independent mechanisms 
through actions upon intracellular signalling, transcription 
factor activity, and gene expression.40–42 The vagus nerve 
is increasingly recognized to be involved in control of 
immune responses. Ingestion of high amounts of dietary fat 
induces release of cholecystokinin that binds to cholecysto-
kinin-receptors on vagal afferents and inhibits the release of 
proinﬂammatory cytokines like tumor necrosis factor-A and 
interleukin-6 from immune-activated macrophages, through 
acetylcholine receptor binding. Based on these ﬁndings, 
high-fat enteral nutrition has been suggested as potentially 
therapeutic in various inﬂammatory disorders.43
Intestinal dysbiosis has recently been suggested as a 
key pathogenetic mechanism in patients with IBS.44 Animal 
models indicate that the intestinal microbiota can inﬂuence 
brain functions, via the gut–brain axis, and conceivably shape 
behavior and mood. In man, enteric infections, antibiotic 
usage, and stress may disturb the indigenous gut ﬂora and 
predispose to IBS.45 Consistently, we have previously shown 
that ingestion of lactulose, an unabsorbable, but fermentable 
carbohydrate, may replicate the gastrointestinal symptoms 
in patients with subjective food hypersensitivity,46 and others 
have shown that reduced intake of dietary carbohydrate 
may beneﬁt patients with IBS.47 Bloating and perception of 
increased gas production are indeed common complaints 
of patients with subjective food hypersensitivity. Intestinal 
gases, such as hydrogen, methane, and carbon dioxide, are 
produced by colonic microbial fermentation. Intriguingly, EPA 
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capsules for 7 days have been found to reduce total breath 
hydrogen excretion after challenge with lactitol, another 
unabsorbable but fermentable carbohydrate.48 EPA contains 
ﬁve double bonds, which potentially can be saturated during 
bacteria metabolism, and thus offer a salvage route for excess 
hydrogen.48 Whether tube administered seal oil, rich in EPA, 
could inﬂuence microbial metabolism is yet not known.
The major limitation of the present pilot study is the lack 
of control. Placebo effects are indeed known to be strong in 
patients with subjective complaints.49 However, as seal oil 
previously improved gastrointestinal symptoms in this patient 
group compared with soy oil,20 we wanted to ﬁrst perform 
an open pilot study to examine if positive effects on also 
nongastrointestinal symptoms could be anticipated. Other 
limitations were lack of diet surveillance and no biological 
(eg, fatty acid proﬁle in blood for validation of intake) or 
objective clinical effect measures.
Conclusion
In conclusion, gastrointestinal, as well as nongastrointestinal 
symptoms, and QoL of patients with subjective food hyper-
sensitivity all improved signiﬁcantly following short-term, 
duodenal administration of seal oil. The apparent effect could 
be mediated through the well-known anti-inﬂammatory 
effects of n-3 PUFAs, but other mechanisms including effects 
on the intestinal microﬂora and placebo effects might also 
be involved. For conﬁrmation of results, further studies with 
placebo are warranted.
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